The stock has a 36-month beta value of -0.55. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RAPP is 17.41M, and at present, short sellers hold a 15.07% of that float. On June 25, 2025, the average trading volume of RAPP was 180.50K shares.
RAPP) stock’s latest price update
The stock price of Rapport Therapeutics Inc (NASDAQ: RAPP) has jumped by 110736 compared to previous close of 10.88. Despite this, the company has seen a gain of 10.54% in its stock price over the last five trading days. marketbeat.com reported 2025-06-12 that The biopharmaceuticals industry is both exciting and risky for investors. Many leading growth stocks in the U.S. market are found in this sector, due to the significant rallies that biopharmaceutical companies experience when a key positive trial result is announced or an important drug receives government approval.
RAPP’s Market Performance
Rapport Therapeutics Inc (RAPP) has experienced a 10.54% rise in stock performance for the past week, with a 11.33% rise in the past month, and a 21.14% rise in the past quarter. The volatility ratio for the week is 6.60%, and the volatility levels for the past 30 days are at 8.81% for RAPP. The simple moving average for the past 20 days is 10.69% for RAPP’s stock, with a -21.91% simple moving average for the past 200 days.
Analysts’ Opinion of RAPP
Stifel gave a rating of “Buy” to RAPP, setting the target price at $35 in the report published on July 02nd of the previous year.
RAPP Trading at 14.91% from the 50-Day Moving Average
After a stumble in the market that brought RAPP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.37% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RAPP starting from Bredt David, who sale 8,500 shares at the price of $11.00 back on Jun 16 ’25. After this action, Bredt David now owns 443,642 shares of Rapport Therapeutics Inc, valued at $93,522 using the latest closing price.
Stock Fundamentals for RAPP
The total capital return value is set at -0.32. Equity return is now at value -33.14, with -31.36 for asset returns.
Based on Rapport Therapeutics Inc (RAPP), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -8.6.
Currently, EBITDA for the company is -77.47 million with net debt to EBITDA at 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 31.01.
Conclusion
To sum up, Rapport Therapeutics Inc (RAPP) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
